摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[2-phenethyl-1-(3,4,5-trimethoxy-benzyl)-1H-benzimidazol-5-yl]-cyclopropanecarboxylic acid hydroxyamide

中文名称
——
中文别名
——
英文名称
2-[2-phenethyl-1-(3,4,5-trimethoxy-benzyl)-1H-benzimidazol-5-yl]-cyclopropanecarboxylic acid hydroxyamide
英文别名
N-hydroxy-2-[2-(2-phenylethyl)-1-[(3,4,5-trimethoxyphenyl)methyl]benzimidazol-5-yl]cyclopropane-1-carboxamide
2-[2-phenethyl-1-(3,4,5-trimethoxy-benzyl)-1H-benzimidazol-5-yl]-cyclopropanecarboxylic acid hydroxyamide化学式
CAS
——
化学式
C29H31N3O5
mdl
——
分子量
501.582
InChiKey
XCVUVBPELUPMTF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    37
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    94.8
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

  • 作为产物:
    参考文献:
    名称:
    [EN] BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS
    [FR] DERIVES DE BENZIMIDAZOLE: PREPARATION ET COMPOSITIONS PHARMACEUTIQUES
    摘要:
    本发明涉及羟肟酸酯化合物,这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地说,本发明涉及含苯并咪唑的化合物及其制备方法。这些化合物可能用作治疗增生性疾病以及涉及组蛋白去乙酰化酶(HDAC)失调的其他疾病的药物。
    公开号:
    WO2005028447A1
点击查看最新优质反应信息

文献信息

  • Benzimidazole derivates: preparation and pharmaceutical applications
    申请人:Chen Dizhong
    公开号:US20070043043A1
    公开(公告)日:2007-02-22
    The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    本发明涉及羟肟酸化合物,其为组蛋白去乙酰化酶的抑制剂。更具体地,本发明涉及含苯并咪唑的化合物及其制备方法。这些化合物可能作为药物用于治疗增殖性疾病以及其他涉及组蛋白去乙酰化酶(HDAC)失调或相关的疾病。
  • BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS
    申请人:Chen Dizhong
    公开号:US20100256138A1
    公开(公告)日:2010-10-07
    The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    本发明涉及羟肟酸类化合物,这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地说,本发明涉及含苯并咪唑的化合物及其制备方法。这些化合物可能作为药物用于治疗增殖性疾病以及与组蛋白去乙酰化酶(HDAC)失调有关的其他疾病。
  • Benzimidazole derivatives: preparation and pharmaceutical applications
    申请人:MEI PHARMA, INC.
    公开号:US10201527B2
    公开(公告)日:2019-02-12
    The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    本发明涉及作为组蛋白去乙酰化酶抑制剂的羟酰胺化合物。更具体地说,本发明涉及含苯并咪唑的化合物及其制备方法。这些化合物可用作治疗增殖性疾病以及涉及组蛋白去乙酰化酶(HDAC)失调或与之有关的其他疾病的药物。
  • BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS
    申请人:S*Bio Pte Ltd
    公开号:EP1673349A1
    公开(公告)日:2006-06-28
  • EP1673349A4
    申请人:——
    公开号:EP1673349A4
    公开(公告)日:2008-01-23
查看更多